<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430740</url>
  </required_header>
  <id_info>
    <org_study_id>AMH1</org_study_id>
    <nct_id>NCT02430740</nct_id>
  </id_info>
  <brief_title>Tailored Ovarian Stimulation Based on BMI, AMH, AFC</brief_title>
  <official_title>Multicentric Randomized Controlled Study to Determine a Tailored Strategy for Controlled Ovarian Stimulation in IVF Based on AMH, BMI and AFC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to develop a tailored based strategy for ovarian stimulation in IVF&#xD;
      patients using AMH, BMI, antral follicle count (AFC).&#xD;
&#xD;
      300 patients will be randomized in 2 arms:&#xD;
&#xD;
        1. control group: standard care rec FSH.&#xD;
&#xD;
        2. study group: modified dose of Rec FSH based on AFC with a correction factor based on BMI&#xD;
           and basal AMH level.&#xD;
&#xD;
      Primary endpoints: number of mature follicles and eggs collected at egg retrieval; amount of&#xD;
      rec FSH used.&#xD;
&#xD;
      Secondary endpoints: fertilization rate; cleavage rate; clinical pregnancy rate; inhibin B&#xD;
      and AMH levels during ovarian stimulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to develop a tailored based strategy for ovarian stimulation in IVF&#xD;
      patients using AMH, BMI, AFC and inhibin B.&#xD;
&#xD;
      300 patients will be stimulated with rec FSH and an antagonist pituitary inhibition protocol,&#xD;
      and randomized (at random computer generated numbers) in 2 arms:&#xD;
&#xD;
        1. control group: standard care recFSH based on age, basal FSH and AFC.&#xD;
&#xD;
        2. study group: modified dose of Rec FSH based on AFC with a correction factor based on BMI&#xD;
           and basal AMH level.&#xD;
&#xD;
      FSH administration: 20IU per antral follicle (from 2-5mm) corrected as follows:&#xD;
&#xD;
      Correction factor for&#xD;
&#xD;
      AMH:&#xD;
&#xD;
      &lt;1 pMol/L X4 1-6 pMol/L X2 7-18 pMol/L X1 &gt;18 pMol/L X0.5 BMI 16.5-18.5 X0.75 18.5-25 X1&#xD;
      25-30 X1.25 30-35 X1.5 35-40 X2 Primary endpoints: number of mature follicles and eggs&#xD;
      collected at egg retrieval; amount of rec FSH used.&#xD;
&#xD;
      Secondary endpoints: fertilization rate; cleavage rate; clinical pregnancy rate; inhibin B&#xD;
      and AMH levels during ovarian stimulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of mature follicles</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of oocytes retrieved</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rec FSH dose used</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cleavage rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMH level during stimulation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibin B level during stimulation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard care recFSH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recFSH</intervention_name>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>Gonal F</other_name>
    <other_name>Puregon</other_name>
    <other_name>Fostimon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female infertile patients eligible for IVF treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  polycystic ovaries&#xD;
&#xD;
          -  untreated thyroid pathology&#xD;
&#xD;
          -  hypogonadotropic hypogonadism&#xD;
&#xD;
          -  untreaed hyperprolactinemia&#xD;
&#xD;
          -  study drug hypersensitivity&#xD;
&#xD;
          -  previous OHSS&#xD;
&#xD;
          -  unilateral ovariectomy&#xD;
&#xD;
          -  genital malformation&#xD;
&#xD;
          -  BMI&gt;40&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine Wyns, MD, PhD</last_name>
    <phone>003227649501</phone>
    <email>christine.wyns@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline Pirard, Md, PhD</last_name>
    <phone>003227644116</phone>
    <email>celine.pirard@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Wyns, MD, PhD</last_name>
      <phone>003227649501</phone>
      <email>christine.wyns@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Céline Pirard, Md, PhD</last_name>
      <phone>003227649501</phone>
      <email>celine.pirard@uclouvain.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Wyns</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Fertilization in Vitro</keyword>
  <keyword>antagonist protocol</keyword>
  <keyword>antral follicle count</keyword>
  <keyword>Anti-Mullerian Hormone</keyword>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

